Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 430Lymphoma, Large B-Cell, Diffuse 97Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Follicular 81Recurrence 72Lymphoma 62Lymphoma, Mantle-Cell 59Neoplasms, Plasma Cell 58Lymphoma, B-Cell, Marginal Zone 47Lymphoma, Non-Hodgkin 46Leukemia, Myeloid, Acute 34Leukemia 32Neoplasms 24Myelodysplastic Syndromes 24Lymphoma, B-Cell 24Waldenstrom Macroglobulinemia 18Hodgkin Disease 18Smoldering Multiple Myeloma 17Lymphoma, T-Cell, Peripheral 16Burkitt Lymphoma 14Hematologic Diseases 13Lymphoma, T-Cell, Cutaneous 12Lymphoma, T-Cell 12Prostatic Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Sezary Syndrome 10Mycosis Fungoides 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Large-Cell, Anaplastic 9Leukemia, Myelomonocytic, Chronic 9

Interventions

Cyclophosphamide 10Doxorubicin 9Vincristine 7Prednisone 7Etoposide 6Brentuximab Vedotin 4prednylidene 3etoposide phosphate 3Bortezomib 3romidepsin 2pembrolizumab 2fludarabine 2duvelisib 2deltacortene 2Vorinostat 2Prednisolone 2Ifosfamide 2tazemetostat 1pirarubicin 1fludarabine phosphate 1cc-486 1Sensitivity and Specificity 1Salvia hispanica seed extract 1Receptors, Chimeric Antigen 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Nivolumab 1Methylprednisolone 1Methotrexate 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enteropathy-Associated T-Cell Lymphoma × Lenalidomide × Clear all
NCT02561273 2023-12-13

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

University of Nebraska

Phase 1/2 Completed
54 enrolled 14 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡